Management Team and Advisors
|
|
|
 |
Ravi Kumar, Ph.D.
Founder
Dr. Ravi Kumar founded ARKAY Therapeutics with a mission to provide sustained glycemic control for Type 2 diabetes patients. He served as the Executive Director and CEO from 2014-19. He is a subject matter expert in translational medicine, clinical development, vendor management and contribution of immune and inflammatory dysfunctions to the pathophysiology of metabolic, cardiovascular, autoimmune and chronic inflammatory diseases. Dr. Kumar is a subject matter expert in translational medicine, clinical development, vendor management and contribution of immune and inflammatory dysfunctions to the pathophysiology of metabolic, cardiovascular, autoimmune and chronic inflammatory diseases. He has over 3 decades of pharmaceutical industry experience in small-to-medium-to-large pharmaceutical companies including Pfizer. Served as the Co-Project Leader of the safer Celebrex (a selective Cox-2 inhibitor) program. Dr. Kumar is the inventor of ARKAY's patent "Formulations and Methods for Treatment of Metabolic Syndrome." He also cloned and characterized the Angiotensin-converting Enzyme (ACE), the key rate-limiting enzyme in the regulation of Renin-Angiotensin-Aldosterone System (RAAS) with a grant award from the AHA over three decades ago at The Cleveland Clinic Foundation. ACE inhibitors are widely used for the clinical management of high blood pressure and hypertension. He obtained M.S. and Ph.D. in Molecular Cell Biology from New York University (NYU) and an Executive Mini-MBA in Biopharma Innovation from Rutgers University Business School.
Read More
|
|
|
 |
Stanley S. Schwartz, MD, FACP, FACE
Chief Medical Advisor
Emeritus Associate Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Dr. Stanley Schwartz has retired from a private practice in Ardmore, PA. where he saw
patients for 12 years. He had previously spent 32 years at the University of
Pennsylvania, leaving as an Emeritus Clinical Associate Professor of Medicine. Dr.
Schwartz received his MD in 1973 from the University of Chicago ; completed his
residency at the University of Pennsylvania; and did a fellowship in endocrinology and
metabolism at the University of Chicago.
Read More
|
|
|
 |
Martin Ogletree, Ph.D.
Chief Scientific Advisor
Former Distinguished Research Fellow & Director of Thrombosis Research, Metabolic &
Cardiovascular Drug Discovery, Bristol-Myers Squibb and Merck
Dr. Martin Ogletree led thrombosis research in Cardiovascular Drug Discovery at Merck Research Labs and at Bristol-Myers Squibb (BMS). At Merck he also led target identification and validation for the cardiovascular franchise. At BMS he led the team that advanced ELIQUIS (apixaban) in drug discovery, preclinical and early clinical development.
Read More
|
|
|
 |
Nancy C. Motola, PhD, RAC
Former Senior Vice President, Regulatory & Quality, Alexion Pharmaceuticals Inc.
Advisor
Dr. Nancy C. Motola, RAC, has over 30 years' experience in the Pharmaceutical Industry, encompassing both small molecules, biologics, and many therapeutic areas, in regulatory affairs and quality assurance, as well as chemical development/manufacturing. Through her consulting company, Pharma Regulatory Connection, she provides strategic Regulatory expertise for small/start-up, as well as large pharma companies.
Read More
|
|
|
 |
Casey Case, Ph.D.
Former Senior Vice President, 4D Molecular Therapeutics
Board Member
Dr. Casey Case is a veteran pharmaceutical industry executive. He has contributed to the success of biopharmaceutical companies such as OSI Pharmaceuticals, Tularik and Sangamo Biosciences.
Read More
|
|
|
 |
Hemant N. Joshi, Ph.D., MBA
Founder, TARA Innovations, LLC.
Advisor
Dr. Hemant Joshi is the founder of Tara Innovations LLC, a Pharmaceutical product development Contract Research Organization (CRO). He has over 27 years' experience as a Pharmaceutical Scientist. Tara is involved in product development, analysis and technology management.
Read More
|
|
|
 |
Paul Jeffrey, M.B.A.
Former Vice President, New Product Development & Commercialization, Pfizer
Board Member
Mr. Paul Jeffrey is an experienced business executive and advisor with over 35 years of pharmaceutical research, product development, marketing and business development experience. As vice president of early commercial development at Pfizer, he was responsible for the commercial development of the entire portfolio of Rx pipeline products in Primary Care.
Read More
|
|
|
 |
Marvin Cohen, Ph.D.
Advisor, Clinical Pharmacology
Marvin Cohen, Ph.D is President and Principal Consultant, MBC Pharma Solutions, LLC. Previously he was most recently Director of Clinical Pharmacology, Bristol-Myers Squibb. Dr. Cohen has a broad background in Pharmaceutical Research and Development for over 30 years in clinical pharmacology, clinical pharmacokinetics, nonclinical pharmacokinetics, and biotransformation in cardiovascular, metabolic diseases, oncology, immuno-oncology, hematology, immunology, neuroscience, infectious diseases, and dermatology therapeutic areas for both large molecule biotherapeutics and small molecules.
Read More
|
|
|
 |
Late Clifford M. Davidson
Intellectual Property Attorney, Founding Partner, Davidson, Davidson & Kappel, LLC
Advisor
Cliff Davidson is a founding partner at Davidson, Davidson & Kappel, LLC, an Intellectual Property law firm with offices in New York. He counsels pharmaceutical clients in pharmaceutical patent-related matters, including patent prosecution, freedom to operate and infringement opinions, due diligence and tech transfer, and litigation. He has assisted pharmaceutical and biotech companies in creating significant and valuable patent portfolios covering their proprietary technologies.
Read More
|
|
|
|
